Even with disease-modifying therapies, patients who have chronically active inflammatory MS lesions can expect an aggressive disease course and poor outcomes. A new study shows that patients with ≥4 ...

WEST PALM BEACH, Fla. -- Tolebrutinib, an investigational brain-penetrant Bruton's tyrosine kinase (BTK) inhibitor, failed to eliminate paramagnetic rim lesions (PRLs) in people with multiple ...

Chronic active lesions, which are identified by their darkened outer rims, are associated with more aggressive multiple sclerosis and earlier disability, according to new research from the National ...

Prospective tracking of "smoldering" chronic active lesions with notable darkened rims in people with multiple sclerosis (MS), previously only detectable upon autopsy, suggests the lesions are linked ...

WEST PALM BEACH, FL – The presence of paramagnetic rim lesions (PRLs) on MRI may help in the diagnosis of multiple sclerosis (MS), as well as in predicting more severe disease course, new research ...

Please provide your email address to receive an email when new articles are posted on . Treatment with tolebrutinib 60 mg for 12 weeks reduced new gadolinium-enhancing and new or enlarging T2 lesions ...

Two-year data on MRI, efficacy, and safety findings from the long-term safety extension study of the investigational Bruton tyrosine kinase (BTK) inhibitor tolebrutinib for relapsing multiple ...

The faster patients can be diagnosed with multiple sclerosis, the sooner they can begin taking the powerful medications that can prevent further brain damage. Subscribe to our newsletter for the ...